NCT06790394招募中1 期
A Test-retest Study to Evaluate the Reproducibility of [18F]Florbetaben PET Imaging in Patients With Cardiac Amyloidosis and Control Patients
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 15
- 试验地点
- 3
- 主要终点
- Test-Retest variability of cardiac [18F]florbetaben PET uptake
研究概览
简要总结
This study is an open-label study to evaluate and characterize test-retest reliability of [18F]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the [18F]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of [18F]florbetaben uptake in the heart will be performed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion criteria (for all subjects):
- •Males and females aged ≥40 years
- •Able to understand, sign, and date written informed consent
- •Written informed consent must be obtained before any assessment is performed
- •Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of child-bearing potential, they must commit to use of a highly effective contraceptive measure for one week after the PET scan (including combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence)
- •Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following each PET scan (including, for female partners of childbearing potential, combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, male subjects with vasectomy or sexual abstinence)
- •Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan
- •Medications taken for treatment of multiple myeloma or chronic diseases of the heart or tafamides treatment are maintained on a stable dosage regimen.
- •Patients on stable coagulation, if arterial blood sampling isperformed.
- •Inclusion criteria for AL-CA and ATTR-CA patients:
- •Patients with a clinical diagnosis of cardiac AL amyloidosis or cardiac ATTR diagnosis according to diagnostic criteria
- •Inclusion criteria for control patients:
- •The control subjects must meet one of the following criteria:
- •Patients without heart failure and no suspicion of cardiac amyloidosis OR
- •Patients with impaired heart function but cardiac amyloidosis ruled out by echocardiography, CMR or cardiac biopsy OR
- •Patients with known plasma cell dyscrasia (MGUS, multiple myeloma) but no clinical signs of cardiac amyloidosis detected by echocardiography or CMR
排除标准
- •Subject has received, in the last 3 months, or currently receives amyloid targeting monoclonal antibody therapy.
- •Any known allergic reactions or hypersensitivity towards any compound of the study drug
- •Hemoglobin value < 10 g/dL
- •Severe hepatic impairment (AST or ALT >5 x ULN; bilirubin >3 x ULN)
- •Subject receives hemodialysis or peritoneal dialysis
- •Inability to lay flat for up to 60 min
- •Pregnant, lactating or breastfeeding
- •Unwilling and/or unable to cooperate with study procedures
- •Having received a PET scan within one week before the 18F]florbetaben PET scan
- •For patients were arterial sampling isperformed: Subject has a contraindication to arterial cannulation, including but not limited to allergy to local anesthetics, peripheral vascular disease, Raynaud's phenomenon as determined by abnormal Allen's test or abnormal coagulation profile at screening.
研究组 & 干预措施
Patients with cardiac disease
Experimental
All eligible AL, ATTR and non-CA patients will receive two injections of the investigational imaging agent florbetaben: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 5 patients of each group will be required.
干预措施: Florbetaben F18 (Drug)
结局指标
主要结局
Test-Retest variability of cardiac [18F]florbetaben PET uptake
时间窗: The duration of the study for participants may be up to 73 days.
Percent Test-Retest variability (%) of cardiac 18F florbetaben PET
次要结局
- Test-Retest variability of extracardiac [18F]florbetaben uptake(The duration of the study for participants may be up to 73 days.)
- Net influx rate derived from full tracer kinetic modelling(The duration of the study for participants may be up to 73 days.)
- Volume of distribution derived from full tracer kinetic modelling(The duration of the study for participants may be up to 73 days.)
- Safety and tolerability of [18F]florbetaben(The duration of the study for participants may be up to 73 days.)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327Healthy ParticipantsIdiopathic Pulmonary Fibrosis (IPF)NCT04069143Bristol-Myers Squibb14
已完成
不适用
Validations of the Computerized Adaptive Testing System of the Functional Assessment of StrokeStrokeNCT05524818Buddhist Tzu Chi General Hospital76
尚未招募
不适用
A pilot study to assess the reliability and validity of the sub domains motor development (*bewegingsactiviteiten*) of the Franciscusoord Development Steps Scale (*Franciscusoord Ontwikkelingensstappen Schaal* (*FOS*)) in the playgroups at Franciscusoordalle aandoeningen, van licht tot ernstig van fysieke aard die leiden tot een achterstand in de motorische ontwikkeling van kinderen.disorders causing a delay in motor developmentNL-OMON32344Stichting Revalidatie Limburg (SRL)45
尚未招募
Unknown
A Study to Evaluate a Portable Body Composition Analyser (Fitrus Light)KCT0009376Cheonan Korean Medicine Hospital of Daejeon University50
已完成
不适用
Evaluation of the Repeatability and Reproducibility of AngioVueNormal, Glaucoma & Retinal PathologyNCT02911883Optovue70